ENLIGHTEN-10

Not yet recruitingPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk

Lead sponsor

Eli Lilly and Company

Asset

Eloralintide

Subcutaneous · Amylin analog

Listed sites

309

Recruiting sites

Estimated enrollment

3,000

Study population

Cardiovascular disease, Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI ≥25•HbA1c 6.5-9.5%

Primary endpoints

•Body Weight•Hemoglobin A1c (HbA1c)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07900633

Org study ID27870

Secondary ID2026-525919-14-00

Secondary IDJ3R-MC-YDASEli Lilly and Company

Timeline

Milestones

Study first posted2026-10-28actual

Last update posted2026-11-03actual

Study start2026-12estimated (month precision)

Primary completion2029-11estimated (month precision)

Study completion2029-12estimated (month precision)

Assets

Investigational agents

Eloralintide

Who this study enrolls

Cardiovascular diseaseObesity / overweightType 2 diabetes

Who can enroll

Minimum age45 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have type 2 diabetes

•Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening

•Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening

•Have an increased risk of cardiovascular events

•Have a BMI ≥ 25.0 kg/m2 at screening

•Have a stable body weight (<5% body weight change) for 90 days prior to screening

•Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Exclusion criteria

•Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)

•Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)

•Have type 1 diabetes

•Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure

•Have had within 60 days prior to screening:

-acute myocardial infarction

-stroke

-hospitalization for congestive heart failure, or

-coronary, peripheral, or carotid artery revascularization procedure

•Have received treatment combining sulfonylurea and insulin within 90 days prior to screening

Endpoints (11)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Cardiometabolic biomarkers

Safety / tolerability / PK

Glycemic / diabetes

Renal / kidney

Patient-reported / QoL

Weight & body composition

3 endpoints

Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 64

percent change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Waist-to-Height Ratio

Time frame:Baseline, Week 64

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 64

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 36

change from baseline, improvement

Renal / kidney

1 endpoint

Secondary/protocol endpoint

Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

Time frame:Baseline, Week 64

change from baseline, improvement

Cardiometabolic biomarkers

3 endpoints

Secondary/protocol endpoint

Change from Baseline in Systolic Blood Pressure

Time frame:Baseline, Week 36

change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in High-Sensitivity C-reactive Protein (hsCRP)

Time frame:Baseline, Week 36

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in Triglycerides

Time frame:Baseline, Week 36

percent change from baseline, improvement

Patient-reported / QoL

1 endpoint

Secondary/protocol endpoint

Change from Baseline in Short Form-36 (SF-36 v2) Score

Time frame:Baseline, Week 64

change from baseline, improvement

Safety / tolerability / PK

2 endpoints

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax,ss)

Time frame:Baseline through Week 64

concentration, descriptive

Secondary/protocol endpoint

PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)

Time frame:Baseline through Week 64

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.